CompletedPhase 4

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

China332 participantsStarted 2013-02-22

Plain-language summary

The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related macular degeneration (AMD) . This study was to provide long-term safety data in the treatment of Chinese patients with wet AMD.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion criteria: * Patients with visual impairment due to neovascular AMD * A qualifying vision score at study entry Key Exclusion criteria * Active infection or inflammation either eye at study entry * Uncontrolled glaucoma in either eye * Any disorder in the study eye which may affect vision * Use of any systemic anti-vascular endothelial growth factor (VEGF)-drugs within 3 months prior to study entry * Previous treatment of the study eye for wet AMD * Any surgery in the study eye 3 months prior to or planned with 6 month after study entry

What they're measuring

Average Change in Visual Acuity (Letters) From Month 3 to Month 4 Through Month 12

Timeframe: Month 3 to month 4 through Month 12

Trial details

NCT IDNCT01775124

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-11-23

Results submitted2016-11-21

View on ClinicalTrials.gov More Neovascular Age-related Macular Degeneration trials